|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2500111394 |
|
最近更新日期: Date of Last Refreshed on: |
2025-10-30 16:17:52 |
|
注册时间: Date of Registration: |
2025-10-30 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
不同治疗方式对肺大疱患者的影响研究 |
|
Public title: |
Study on the Impact of Different Treatment Methods on Patients with Pulmonary Bullae |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
不同治疗方式对肺大疱患者的影响研究 |
|
Scientific title: |
Study on the Impact of Different Treatment Methods on Patients with Pulmonary Bullae |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
李洪海 |
研究负责人: |
王钰琦 |
|
Applicant: |
Li,Honghai |
Study leader: |
Wang Yuqi |
|
申请注册联系人电话: Applicant telephone: |
+86 177 3310 8291 |
研究负责人电话: Study leader's telephone: |
+86 136 0127 9155 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
pla301lhh@163.com |
研究负责人电子邮件: Study leader's E-mail: |
wyq301@qq.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
北京市海淀区复兴路28号 |
研究负责人通讯地址: |
北京市海淀区复兴路28号 |
|
Applicant address: |
No. 28, Fuxing Road, Haidian District, Beijing |
Study leader's address: |
No. 28, Fuxing Road, Haidian District, Beijing |
|
申请注册联系人邮政编码: Applicant postcode: |
100853 |
研究负责人邮政编码: Study leader's postcode: |
100853 |
|
申请人所在单位: |
解放军总医院第一医学中心 |
||
|
Applicant's institution: |
The First Medical Center of the PLA General Hospital |
||
|
研究负责人所在单位: |
解放军总医院第一医学中心 |
||
|
Affiliation of the Leader: |
The First Medical Center of the PLA General Hospital |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
S2025-621-01 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
中国人民解放军总医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Medical Ethics Committee of Chinese PLA General Hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-08-14 00:00:00 |
||
|
伦理委员会联系人: |
曹江 |
||
|
Contact Name of the ethic committee: |
Cao Jiang |
||
|
伦理委员会联系地址: |
北京市海淀区复兴路28号 |
||
|
Contact Address of the ethic committee: |
No. 28, Fuxing Road, Haidian District, Beijing |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 10 6693 7166 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
解放军总医院第一医学中心 |
||||||||||||||||||||||
|
Primary sponsor: |
The First Medical Center, Chinese PLA General Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
北京市海淀区复兴路28号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
28 Fuxing Road, Haidian District, Beijing |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
国家自然科学基金资助项目:U21A20480 |
||||||||||||||||||||||
|
Source(s) of funding: |
National Natural Science Foundation of China (Project No. U21A20480). |
||||||||||||||||||||||
|
Target disease: |
bullae of lung |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
回顾性研究 | ||||||||||||||||||||||
|
Study phase: |
Retrospective study |
||||||||||||||||||||||
|
研究设计: |
队列研究 |
||||||||||||||||||||||
|
Study design: |
Cohort study |
||||||||||||||||||||||
|
研究目的: |
对于难治性大疱性肺疾病的最佳干预措施仍存在争议,有创性外科手术(SO)和微创支气管内瓣膜(EBV)之间的选择。全面比较它们的长期疗效、安全性和成本对临床决策至关重要。比较SO与EBV的围手术期结局、1年疗效、长期无复发生存率和经济影响。 |
||||||||||||||||||||||
|
Objectives of Study: |
The optimal intervention for refractory bullae lung disease remains debated, with a choice between invasive surgical operation (SO) and the minimally invasive endobronchial valve (EBV) . A comprehensive comparison of their long-term efficacy, safety, and cost is crucial for clinical decision-making.?To compare the perioperative outcomes, 1-year efficacy, long-term recurrence-free survival, and economic impact of SO versus EBV . |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1.年龄18-80岁 2.胸部CT确诊肺大疱(直径>=3cm或占据单侧胸腔>=20%),符合手术或介入治疗指征, 3.患者遵出院医嘱术后1个月,6个月,1年,3年于我院复诊的病人。 |
||||||||||||||||||||||
|
Inclusion criteria |
1. Age 18–80 years 2. Chest CT-confirmed pulmonary bullae (diameter ≥3 cm or occupying ≥20% of unilateral pleural cavity), meeting criteria for surgical or interventional treatment 3. Patients who comply with discharge instructions and attend follow-up appointments at our hospital at 1 month, 6 months, 1 year, and 3 years post-surgery. |
||||||||||||||||||||||
|
排除标准: |
1.合并肺癌、肺结核等其他肺部疾病; 2.严重心肝肾功能不全;既往肺手术史; 3.患者未遵出院医嘱术后1个月,6个月,1年,3年未于我院复诊的病人。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Concurrent pulmonary conditions such as lung cancer or tuberculosis; 2. Severe cardiac, hepatic or renal insufficiency; prior history of pulmonary surgery; 3. Patients who failed to attend follow-up appointments at our hospital at 1 month, 6 months, 1 year or 3 years post-discharge as per discharge instructions. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-08-15 00:00:00至 To 2025-10-15 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2025-08-15 00:00:00 至 To 2025-10-14 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
所有的CT都由两名经验丰富的放射科医生独立审查,他们对临床数据一无所知。 |
|
Blinding: |
All scans were reviewed independently by two experienced radiologists who were blinded to the clinical data. |
|
是否共享原始数据: IPD sharing |
Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
数据获取提案应发送至wyq301@qq.com;须签署数据获取协议。研究公开发表后1年可以共享,可以通过邮箱获取数据。 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Data acquisition proposals should be sent to wyq301@qq.com; a data acquisition agreement must be signed. Data can be shared one year after the research is publicly published and can be obtained via email. |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
采用电子表格记录病例记录表(Case Record Form, CRF),使用医院的电子采集和管理系统(Electronic DataCapture, EDC)管理数据 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Case Record Forms (CRFs) are recorded using electronic spreadsheets, and data is managed through the hospital's Electronic Data Capture (EDC) system. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |